What is the most appropriate hypnotic medication for an otherwise healthy adult who needs to maintain sleep throughout the night?

Best Sleep Medication for Staying Asleep

For an otherwise healthy adult with sleep maintenance insomnia (difficulty staying asleep throughout the night), use suvorexant, eszopiclone, doxepin, temazepam, or zolpidem—all have evidence-based support specifically for sleep maintenance. Among these options, I recommend eszopiclone (2-3 mg) or suvorexant (10-20 mg) as first-line choices based on their specific efficacy for sleep maintenance with acceptable safety profiles 1.

Evidence-Based Medication Options for Sleep Maintenance

The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline specifically identifies medications with proven efficacy for sleep maintenance insomnia 1:

Primary Recommendations for Sleep Maintenance:

Eszopiclone (2-3 mg):

• Explicitly recommended for both sleep onset AND sleep maintenance insomnia 1
• Demonstrated 45-minute increase in total sleep time and 11-minute reduction in wake after sleep onset (WASO) compared to placebo 2
• Achieved 50% remission rate (ISI score <7) at 12 weeks versus 19% with placebo 2
• Unique among non-benzodiazepines with long-term efficacy data up to 12 months 3
• Caution: Most common side effect is unpleasant taste; also associated with somnolence and myalgias 2

Suvorexant (10-20 mg):

• Orexin receptor antagonist specifically recommended for sleep maintenance insomnia 1
• Works by blocking wake-promoting orexin signaling rather than enhancing GABA
• Recent 2023 network meta-analysis supports daridorexant (newer orexin antagonist) for sleep maintenance 4
• Advantage: Different mechanism may have lower abuse potential than GABA-ergic agents

Doxepin (3-6 mg):

• Low-dose tricyclic specifically recommended for sleep maintenance insomnia 1
• Works via histamine H1 receptor antagonism at low doses
• Advantage: Not a controlled substance; lower abuse potential

Temazepam (15 mg):

• Benzodiazepine recommended for both sleep onset and maintenance 1
• Intermediate half-life provides sustained sleep without excessive morning sedation 5
• Caution: Benzodiazepines carry risks of dependence, tolerance, and potential association with dementia (HR 2.34) 2

Zolpidem (10 mg):

• Recommended for both sleep onset and maintenance 1
• Most widely prescribed hypnotic in the US 6
• 2023 meta-analysis showed zolpidem improved all objective sleep parameters including WASO 4
• Caution: Associated with daytime drowsiness (OR 1.82), complex sleep behaviors, and memory impairment 2, 4

Medications to AVOID for Sleep Maintenance

The AASM guideline explicitly recommends AGAINST several commonly used agents 1:

• Trazodone (50 mg) - insufficient evidence despite widespread off-label use
• Diphenhydramine - not recommended; anticholinergic effects particularly problematic in elderly
• Melatonin (2 mg) - not effective for sleep maintenance
• Valerian, L-tryptophan - insufficient evidence

Clinical Decision Algorithm

Step 1: Choose based on patient-specific factors:

• If concerned about abuse potential or long-term use: Start with doxepin (3-6 mg) or suvorexant (10-20 mg)
• If need for sustained sleep maintenance with established long-term data: Use eszopiclone (2-3 mg)
• If patient has failed other agents: Consider temazepam (15 mg), recognizing benzodiazepine risks

Step 2: Dosing considerations:

• Use FDA-recommended doses (many trials used higher doses than approved) 2
• Women and elderly require lower doses for all agents
• Allow at least 8 hours before arising to minimize residual effects 6

Step 3: Duration of treatment:

• Limit benzodiazepine receptor agonists (zolpidem, eszopiclone, temazepam) to short-term use when possible
• After 1-2 weeks of use, can discontinue abruptly 7
• After >2 weeks, taper gradually by 10-25% weekly to avoid withdrawal 7
• Consider intermittent dosing rather than nightly use for chronic cases 5

Critical Caveats

All recommendations are "WEAK" in the AASM guideline 1, meaning clinical judgment and patient preferences should guide final selection. However, these are the only medications with positive evidence for sleep maintenance.

Large placebo response: Studies show 42-48% of placebo patients report improvement, with 30-39 minute improvements in sleep parameters 2. Set realistic expectations.

Avoid zaleplon and triazolam: These ultra-short-acting agents are specifically indicated only for sleep ONSET, not maintenance 1, 8.

Cognitive behavioral therapy for insomnia (CBT-I) remains first-line treatment and should accompany or precede pharmacotherapy when accessible (RR 1.68 for successful discontinuation) 7, 9.